Quick Answer
Oruka Therapeutics, Inc. reported R&D Expense of $100.64 million for fiscal year 2025.
Oruka Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $100.64M | +34.1% |
| 2024 | $75.06M | +7309.7% |
| 2023 | $1.01M | -78.7% |
| 2022 | $4.75M | -65.7% |
| 2021 | $13.83M | +177.1% |
| 2020 | $4.99M | +172.3% |
| 2019 | $1.83M | -56.8% |
| 2018 | $4.24M | -69.9% |
| 2017 | $14.08M | +14.0% |
| 2016 | $12.35M | +74.8% |
| 2015 | $7.06M | +25.6% |
| 2014 | $5.62M | +92.1% |
| 2013 | $2.93M | +168.1% |
| 2012 | $1.09M | -52.8% |
| 2011 | $2.31M | -25.5% |
| 2010 | $3.11M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $28.99M | +12.8% | +20.3% |
| June 30, 2025 | $24.09M | +29.0% | +20.9% |
| March 31, 2025 | $19.93M | +283.7% | -22.4% |
| September 30, 2024 | $25.69M | +7878.6% | +37.6% |
| June 30, 2024 | $18.67M | +7251.6% | +259.6% |
| March 31, 2024 | $5.19M | +1231.5% | +1512.7% |
| September 30, 2023 | $322.0K | -68.6% | +26.8% |
| June 30, 2023 | $254.0K | -82.9% | -34.9% |
- Oruka Therapeutics, Inc. showed an increase of +34.1% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Oruka Therapeutics, Inc.’s r&d expense has grown by 3140.2% (from $3.11 million to $100.64 million).
- The most recent figure is from Oruka Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: